FDA One Step Closer To Makena Withdrawal After Hearing Officer Echoes Advisory Panel’s Advice

In a memo to Commissioner Califf and Chief Scientist Bumpus, Celia Witten focuses the final Makena decisionmakers on the key factors she believes should be used to determine the drug’s market status.